JP2025517106A5 - - Google Patents

Info

Publication number
JP2025517106A5
JP2025517106A5 JP2024563976A JP2024563976A JP2025517106A5 JP 2025517106 A5 JP2025517106 A5 JP 2025517106A5 JP 2024563976 A JP2024563976 A JP 2024563976A JP 2024563976 A JP2024563976 A JP 2024563976A JP 2025517106 A5 JP2025517106 A5 JP 2025517106A5
Authority
JP
Japan
Prior art keywords
group
alkyl
pharmaceutically acceptable
independently selected
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024563976A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025517106A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/077272 external-priority patent/WO2023207283A1/en
Publication of JP2025517106A publication Critical patent/JP2025517106A/ja
Publication of JP2025517106A5 publication Critical patent/JP2025517106A5/ja
Pending legal-status Critical Current

Links

JP2024563976A 2022-04-28 2023-02-20 Parp1阻害剤としての化合物 Pending JP2025517106A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/089986 2022-04-28
CN2022089986 2022-04-28
PCT/CN2023/077272 WO2023207283A1 (en) 2022-04-28 2023-02-20 Compounds as parp1 inhibitiors

Publications (2)

Publication Number Publication Date
JP2025517106A JP2025517106A (ja) 2025-06-03
JP2025517106A5 true JP2025517106A5 (cg-RX-API-DMAC10.html) 2026-02-27

Family

ID=88517229

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024563976A Pending JP2025517106A (ja) 2022-04-28 2023-02-20 Parp1阻害剤としての化合物

Country Status (6)

Country Link
US (1) US20250289814A1 (cg-RX-API-DMAC10.html)
EP (1) EP4514795A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025517106A (cg-RX-API-DMAC10.html)
KR (1) KR20250033148A (cg-RX-API-DMAC10.html)
CN (1) CN119487027A (cg-RX-API-DMAC10.html)
WO (1) WO2023207283A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120081844A (zh) 2022-01-21 2025-06-03 新特拉有限公司 Parp1抑制剂及其用途
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
PT4497438T (pt) 2022-04-28 2025-10-31 Xinthera Inc C/O Gilead Sciences Inc Inibidores tricíclicos da parp1 e suas utilizações
TW202416977A (zh) * 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途
KR20260100685A (ko) * 2023-10-23 2026-06-30 길리애드 사이언시즈, 인코포레이티드 Parp1 저해제 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0906294T1 (en) * 1996-05-29 2003-04-30 Warner-Lambert Company Benzoxazinone dopamine d4 receptor antagonists
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds
EP1758895A1 (en) * 2004-06-17 2007-03-07 Wyeth a Corporation of the State of Delaware Gonadotropin releasing hormone receptor antagonists
WO2009053373A1 (en) * 2007-10-26 2009-04-30 Janssen Pharmaceutica Nv Quinolinone derivatives as parp inhibitors
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
EP2415767B1 (en) * 2009-03-27 2014-09-03 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) Polymerase (PARP) Inhibitors
TWI837403B (zh) * 2019-07-19 2024-04-01 瑞典商阿斯特捷利康公司 化學化合物
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
WO2022228387A1 (en) 2021-04-26 2022-11-03 Fochon Biosciences, Ltd. Compounds as parp inhibitors
TWI876212B (zh) 2021-10-01 2025-03-11 美商辛瑟拉股份有限公司 吖丁啶及吡咯啶parp1抑制劑及其用途
TW202416977A (zh) 2022-09-30 2024-05-01 大陸商中國醫藥研究開發中心有限公司 含氮雜環類化合物及其醫藥用途

Similar Documents

Publication Publication Date Title
JP2023540228A5 (cg-RX-API-DMAC10.html)
US6762204B2 (en) Taxol enhancer compounds
EP2799437B1 (en) Quinoline and cinnoline derivatives and use thereof
KR102796209B1 (ko) 키나아제 억제제로서의 시클릭 이미노피리미딘 유도체
TWI773730B (zh) 治療性樹枝狀聚合物
RU2005100842A (ru) Производные 8-гидроксихинолина
JP2020527173A5 (cg-RX-API-DMAC10.html)
CN107382966B (zh) 一类荜茇酰胺-川芎嗪杂合物、制备方法及医药用途
JP2017534657A (ja) 新型シチジン誘導体およびその適用
AU2019331665A1 (en) Heterocyclic compounds as AHR modulators
JP2018529643A5 (cg-RX-API-DMAC10.html)
CN101426770A (zh) 用作edg-1拮抗剂的咪唑衍生物
CN110156783B (zh) 作为pi3k/mtor抑制剂的嘧啶基取代的稠合喹啉化合物
CN103113386B (zh) 氮杂环取代二氢青蒿素衍生物及其应用
CA3179325A1 (en) Kinase inhibitors and uses thereof
CN103476769B (zh) 抗癌剂
JP2022552019A5 (cg-RX-API-DMAC10.html)
CN104250253A (zh) 取代四氢化萘酰胺类化合物及其药学上可接受的盐及制备方法和应用
WO1996028447A1 (en) Pyrrolocarbazole derivatives
CN106946868A (zh) 一氧化氮供体型香豆素衍生物、其制备方法及医药用途
JP5701387B2 (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用
CN108707145B (zh) 含五元杂环结构的喹啉类化合物及其制备和应用
JP2021534084A5 (cg-RX-API-DMAC10.html)
JP7302090B2 (ja) ベンゾフラン系n-アシルヒドラゾン誘導体およびそれを含む薬学的組成物
CN102617502A (zh) 一类苯并噁唑衍生物及其医药应用